In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in phase II kidney trial: Ingelheim, Germany Thursday, January 29, 2026, 10:00 Hrs [IST] Bo ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...

Advances in structure-activity relationship studies, computational modeling, and rational combination strategies are accelerating progress toward clinical development. Inconsistencies in clinical ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

Dr. James McCaffrey presents a complete end-to-end demonstration of linear regression with pseudo-inverse training implemented using JavaScript. Compared to other training techniques, such as ...

What FM Nirmala Sitharaman announced on infrastructure, banking, health, education and tourism. Follow The Hindu for more ...

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer ...

Dell's Alienware Area-51 laptop redefines high-performance computing, boasting an Intel Core Ultra 9 and RTX 5090 for ...

DelveInsight's DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

The DUB inhibitors market is poised for steady growth, driven by rising interest in targeted protein degradation and novel oncology therapeutics. The growing prevalence of cancer and neurodegenerative ...